Hiroo Nakashima

Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis

K. Oniki, K. Nakagawa, J. Saruwatari, 2015, PloS one.

Impact of the Superoxide Dismutase 2 Val16Ala Polymorphism on the Relationship between Valproic Acid Exposure and Elevation of γ-Glutamyltransferase in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis

K. Oniki, J. Saruwatari, S. Kaneko, 2014, PloS one.

Effects of CYP2C19 and P450 Oxidoreductase Polymorphisms on the Population Pharmacokinetics of Clobazam and N-Desmethylclobazam in Japanese Patients With Epilepsy

K. Nakagawa, J. Saruwatari, S. Kaneko, 2014, Therapeutic drug monitoring.

Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis

N. Yasui-Furukori, K. Oniki, J. Saruwatari, 2016, Pharmacogenetics and genomics.

Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders

J. Saruwatari, S. Tsuchimine, Naoki Ogusu, 2014, Pharmacogenomics and personalized medicine.